Recent Advances in Drug Delivery Nanocarriers for Targeting Hepatocellular Carcinoma
Recent Advances in Drug Delivery Nanocarriers for Targeting Hepatocellular Carcinoma
复制标题
DOI：
10.1155/2022/7798919
复制
发表时间：
2022-07
影响因子：
--
通讯作者：
Shanshan Wang;Qian-zhou Lv;Xiaoyu Li
中科院分区：
文献类型：
--
作者：
Shanshan Wang;Qian-zhou Lv;Xiaoyu Li
由于中晚期治疗无效，肝细胞癌是全球癌症相关死亡的主要驱动因素之一--药物递送治疗技术有望解决这一问题。药物输送的有效治疗技术需要使用高效和安全的药物载体，而最近药物输送纳米载体的改进已经对肝癌靶向输送产生了重大影响。这些纳米载体包括脂质体、胶束、纳米胶囊、聚合物、外切体和无机纳米颗粒，具有颗粒小、生物相容性和生物降解性好、免疫原性低、缓释和控释能力强、独特的光学、磁学和热学性质、高载药率和易于靶向配体的表面修饰等独特性能。此外，研究表明，这些纳米载体可以实现被动靶向或主动靶向的效果，从而提高药物的治疗效果，减少其副作用。本文就纳米载体靶向肝癌的一些最新研究进展作一简要综述。
Hepatocellular carcinoma (HCC) is among the primary drivers of cancer-related death globally, owing to the ineffectiveness of treatments in intermediate and terminal stages—an issue that drug delivery therapy techniques are expected to address. Drug delivery that works therapeutic techniques necessitates the use of efficient and safe drug carriers, and recent improvements in drug delivery nanocarriers have had a significant impact on HCC targeted delivery. These nanocarriers, including liposomes, micelles, nanocapsules, polymers, exosomes, and inorganic nanoparticles, are accompanied by favorable unique properties such as small particle size, good biocompatibility and biodegradability, low immunogenicity, sustained and controlled release capacity, unique optical, magnetic and heat properties, high drug loading efficiency, and easy surface modification with targeting ligands. Moreover, studies have shown that these nanocarriers can achieve passive targeting or active targeting effect, which improves the therapeutic efficacy of drugs and decreases their side effects. In this paper, we provide a brief overview of some latest studies about nanocarriers for targeting HCC.